Organogenesis HoldingsORGO
About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Employees: 869
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
145% more call options, than puts
Call options by funds: $299K | Put options by funds: $122K
34% more capital invested
Capital invested by funds: $200M [Q4 2024] → $268M (+$68.3M) [Q1 2025]
12% more funds holding
Funds holding: 119 [Q4 2024] → 133 (+14) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 45
0.76% less ownership
Funds ownership: 49.74% [Q4 2024] → 48.98% (-0.76%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Drew Ranieri | 84%upside $6 | Equal-Weight Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ORGO published over the past 30 days









